Compare KBSX & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBSX | GRML |
|---|---|---|
| Founded | 1976 | N/A |
| Country | Taiwan | United States |
| Employees | 394 | 5 |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 51.5M |
| IPO Year | N/A | 2022 |
| Metric | KBSX | GRML |
|---|---|---|
| Price | $1.43 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 102.1K | ★ 2.9M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.65 | N/A |
| Revenue Next Year | $16.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $0.27 |
| 52 Week High | $2.52 | $0.55 |
| Indicator | KBSX | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 38.33 |
| Support Level | $1.32 | $0.31 |
| Resistance Level | $1.61 | $0.43 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 75.86 | 7.82 |
FST Corp is a renowned manufacturer and innovator in the golf industry with a growing portfolio of creative golf products, including acclaimed golf club shafts and other equipment. The Company has engaged in the research, development, manufacturing, and sales of golf club shafts. The Company currently produces and sells golf club shafts under the Company's own high performance KBS golf club shaft brand, and serves as an original equipment manufacturer (OEM) and original design manufacturer (ODM) for other world-renowned golf equipment brands, golf equipment OEMs, and golf equipment distributors that provide consumers with customized golf club services.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.